CD8A and triple-negative breast carcinoma: Third, we apply the model to immunotherapy of triple-negative breast cancer and compare the simulations of spatial distribution of immune cells (e.g., CD8+ and FoxP3+ T cells) with our recent digital pathology quantitative analysis of patients’ specimens.